Endometrial Stromal Sarcoma Overview

Save information for later
Sign Up

Learn About Endometrial Stromal Sarcoma

What is the definition of Endometrial Stromal Sarcoma?
Endometrial stromal sarcoma is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the uterus. Endometrial stromal sarcoma, specifically, develops in the supporting connective tissue (stroma) of the uterus. Signs and symptoms of the condition include abnormal uterine bleeding (i.e. bleeding that is not part of menstrual periods or bleeding after menopause); abdominal pain and/or distension; and frequent urination. The exact underlying cause of Endometrial stromal sarcoma is currently unknown. Most cases occur sporadically in people with no family history of the condition.
What are the alternative names for Endometrial Stromal Sarcoma?
  • Endometrial stromal sarcoma
  • ESS
Who are the top Endometrial Stromal Sarcoma Local Doctors?
Andrew Berchuck
Distinguished in Endometrial Stromal Sarcoma
Dr. Andrew Berchuck
Gynecologic Oncology
Distinguished in Endometrial Stromal Sarcoma
Dr. Andrew Berchuck
Gynecologic Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Berchuck is a Gynecologic Oncologist in Durham, North Carolina. Dr. Berchuck is rated as a Distinguished provider by MediFind in the treatment of Endometrial Stromal Sarcoma. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Tubal Ligation, and Oophorectomy. Dr. Berchuck is currently accepting new patients.

Brittany A. Davidson
Distinguished in Endometrial Stromal Sarcoma
Dr. Brittany A. Davidson
Gynecologic Oncology
Distinguished in Endometrial Stromal Sarcoma
Dr. Brittany A. Davidson
Gynecologic Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brittany Davidson is a Gynecologic Oncologist in Durham, North Carolina. Dr. Davidson is rated as a Distinguished provider by MediFind in the treatment of Endometrial Stromal Sarcoma. Her top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, and Ovarian Carcinosarcoma. Dr. Davidson is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Laura J. Havrilesky
Distinguished in Endometrial Stromal Sarcoma
Dr. Laura J. Havrilesky
Gynecologic Oncology
Distinguished in Endometrial Stromal Sarcoma
Dr. Laura J. Havrilesky
Gynecologic Oncology

Duke Cancer Center Gynecology Clinic

20 Duke Medicine Cir, 
Durham, NC 
919-668-6688
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Laura Havrilesky is a Gynecologic Oncologist in Durham, North Carolina. Dr. Havrilesky is rated as a Distinguished provider by MediFind in the treatment of Endometrial Stromal Sarcoma. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Hysterectomy, and Oophorectomy. Dr. Havrilesky is currently accepting new patients.

View All Doctors
What are the latest Endometrial Stromal Sarcoma Clinical Trials?
A Phase II Study Evaluating the Safety and Efficacy of MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment in Patients With Advanced Soft Tissue Sarcoma
A Phase II Study Evaluating the Safety and Efficacy of MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment in Patients With Advanced Soft Tissue Sarcoma
Enrollment Status: Recruiting
Publish Date: July 24, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2

Summary: This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients with Locally Advanced/ Metastatic LGESS
Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients with Locally Advanced/ Metastatic LGESS
Who is this study for: Patients with Low Grade Endometrial Stromal Sarcoma
Enrollment Status: Recruiting
Publish Date: March 21, 2025
Intervention Type: Drug
Study Drug: Aromatase Inhibitors
Study Phase: Phase 2

Summary: The primary objective is to compare the progression-free survival (PFS) between aromatase inhibitors interruption and aromatase inhibitors maintenance strategies in patients with a locally advanced or metastatic Low Grade Endometrial Stromal Sarcoma (LGESS).

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center